Toward a universal influenza virus vaccine: Some cytokines may fulfill the request

Cytokine. 2021 Dec:148:155703. doi: 10.1016/j.cyto.2021.155703. Epub 2021 Sep 20.

Abstract

The influenza virus annually causes widespread damages to the health and economy of the global community. Vaccination is currently the most crucial strategy in reducing the number of patients. Genetic variations, the high diversity of pandemic viruses, and zoonoses make it challenging to select suitable strains for annual vaccine production. If new pandemic viruses emerge, it will take a long time to produce a vaccine according to the new strains. In the present study, intending to develop a universal influenza vaccine, new bicistronic DNA vaccines were developed that expressed NP or NPm antigen with one of modified IL-18/ IL-17A/ IL-22 cytokine adjuvants. NPm is a mutant form of the antigen that has the ability for cytoplasmic accumulation. In order to investigate and differentiate the role of each of the components of Th1, Th2, Th17, and Treg cellular immune systems in the performance of vaccines, Treg competent and Treg suppressed mouse groups were used. Mice were vaccinated with Foxp3-FC immunogen to produce Treg suppressed mouse groups. The potential of the vaccines to stimulate the immune system was assessed by IFN-γ/IL-17A Dual FluoroSpot. The vaccine's ability to induce humoral immune response was determined by measuring IgG1, IgG2a, and IgA-specific antibodies against the antigen. Kinetics of Th1, Th2, and Th17 cellular immune responses after vaccination, were assessed by evaluating the expression changes of IL-17A, IFN-γ, IL-18, IL-22, IL-4, and IL-2 cytokines by semi-quantitative real-time RT-PCR. To assess the vaccines' ability to induce heterosubtypic immunity, challenge tests with homologous and heterologous viruses were performed and then the virus titer was measured in the lungs of animals. Evaluation of the data obtained from this study showed that the DNA-vaccines coding NPm have more ability to induces a potent cross-cellular immune response and protective immunity than DNA-vaccines coding NP. Although the use of IL-18/ IL-17A/ IL-22 genetic adjuvants enhanced immune responses and protective immunity, Administration of NPm in combination with modified IL-18 (Igk-mIL18-IgFC) induced the most effective immunity in Treg competent mice group.

Keywords: Cross-reactive cellular immunity; Interleukin-18; Molecular Adjuvant; Nucleoprotein; Universal influenza virus vaccine.

MeSH terms

  • Adjuvants, Immunologic / pharmacology
  • Animals
  • Antibody Formation / drug effects
  • Antigens, Viral / immunology
  • Body Weight
  • Cytokines / metabolism*
  • Humans
  • Immunization
  • Influenza Vaccines / immunology*
  • Interferon-gamma / metabolism
  • Interleukin-17
  • Mice
  • Orthomyxoviridae Infections / immunology
  • Orthomyxoviridae Infections / prevention & control
  • Orthomyxoviridae Infections / virology
  • Th1 Cells / immunology
  • Th2 Cells / immunology
  • Vaccines, DNA / immunology

Substances

  • Adjuvants, Immunologic
  • Antigens, Viral
  • Cytokines
  • Influenza Vaccines
  • Interleukin-17
  • Vaccines, DNA
  • Interferon-gamma